ACXP
Acurx Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.42
+1.43%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.4x
Market Cap
$7.77M
MomentumView details →
1D Return
+1.43%
YTD Return
−43.78%
RSI (14)
44.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.4x
Market Cap
$7.77M
RSI (14)
44.9
MomentumView details →
1D Return
+1.43%
YTD Return
−43.78%
SummaryUpdated Jun 1, 2026
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Staten Island, New York. The company went public in June 2021 and focuses on developing novel antibiotics to treat serious bacterial infections. Acurx's primary focus is advancing its lead drug candidate, ibezapolstat, through clinical trials for treating Clostridium difficile infections, a potentially life-threatening condition that affects hundreds of thousands of patients annually.
Similar companies
Latest newsMore news →
Acurx Pharmaceuticals received conditional acceptance from the FDA and trademark allowance from the USPTO for the brand name CIFBEZY for its drug candidate ibezapolstat.19d agoThe FDA provided regulatory guidance to Acurx Pharmaceuticals in meeting minutes from a July 13, 2026 Type C Meeting, indicating openness to a single Phase 3 trial registration plan for ibezapolstat and agreeing that a successful IBZ-ASPIRE trial supported by the IBZ-PATHFINDER Phase 2 trial could allow an NDA filing for both treatment and reduction of recurrence of C. difficile infection.33d ago